- Companies
- New England Patriots
New England Patriots Valuation, Funding & Investors
New England Patriots is valued at $9B as of September 2025.
Last New England Patriots valuation
$9B
Undisclosed stage · Sep 2025
Last New England Patriots funding round
$720M
Undisclosed stage · Sep 2025
Cumulative funding New England Patriots raised
$720M
across 1 funding round
Key investors in New England Patriots
Sixth Street
C. Dean Metropoulos
About New England Patriots
New England Patriots is a professional American football franchise competing in the NFL's AFC East division. Foxboro-headquartered at Gillette Stadium since 2002, the team plays home games in Foxborough, Massachusetts, and fields players like quarterback Drake Maye. Established in 1959 as the Boston Patriots, it holds six Super Bowl titles and maintains fan engagement through patriots.com with stats, tickets, and merchandise.
Founded
1959
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Product sales
Valuation
$9B (Sep 2025)
Sectors
New England Patriots Valuation
New England Patriots is currently valued at $9B, based on its undisclosed-stage round in September 2025.
The $720M round was led by C. Dean Metropoulos and Sixth Street.
New England Patriots valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2025 | Undisclosed stage | $9B |
New England Patriots Funding History
New England Patriots has raised a total of $720M across 1 funding round.
New England Patriots funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2025 | Undisclosed stage | C. Dean Metropoulos (lead); Sixth Street (lead) | $720M | $9B | The New England Patriots agreed to sell an 8% stake in the NFL franchise in September 2025, with billionaire C. Dean Metropoulos purchasing 5% and private equity firm Sixth Street acquiring 3%, at a franchise valuation exceeding US$9 billion. This marks the second-highest NFL team valuation, behind the New York Giants at over $10 billion, and represents Sixth Street's first NFL investment following league policy changes. The Kraft family, who bought the team for $172 million in 1994, retains over 90% ownership, with proceeds intended for reinvestment into the franchise; the deal excludes the New England Revolution MLS team and awaits NFL owners' approval in October 2025. CNBC estimated the Patriots' worth at $9.25 billion prior to the announcement, ranking it fifth among NFL franchises. |
Who has invested in New England Patriots?
2 investors have backed New England Patriots across its funding rounds, including Sixth Street and C. Dean Metropoulos.
Lead investors include C. Dean Metropoulos and Sixth Street.
New England Patriots Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 2 New England Patriots investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialInvestments by New England Patriots
New England Patriots has invested in 1 company to date.
Latest investment by New England Patriots was on June 8th 2015. New England Patriots invested in Spero Therapeutics in their $30M Series A round.
Latest Investments by New England Patriots
| Description | Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
| HQ Country | |
| HQ City | Cambridge |
| Deal Date | 8 Jun 2015 |
| Round | Series A |
| Raised | $30M |
| Investors | GSK; SR One; Atlas Venture; Merck Global Health Innovation Fund; Lundbeckfonden Ventures; The Kraft Group; Partners Innovation Fund |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all New England Patriots investments and their VC round multiples. Start Free Trial | |
New England Patriots Competitors
New England Patriots competitors include listed companies like MSG Sports and TKO, and private ones like Suning Sports, Cleveland Browns, Columbus Crew SC and Chicago Bears.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $2.6B | - | ||
| Private | $658M | $102M | $9B | 13.7x | ||
| Private | - | - | $9B | - | ||
| Private | - | - | $8.9B | - | ||
| Publicly listed | $1.2B | $39M | $9.5B | 9.2x | ||
| Publicly listed | $4.7B | $1.3B | $14B | 4.2x |
New England Patriots Public Comps
New England Patriots is still privately-owned, but its public comps include MSG Sports, TKO, Manchester United, Atlanta Braves Holdings, Juventus FC, Ollamani, Borussia Dortmund, Fenerbahce SK, Olympique Lyon and Parken Sport.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.2B | $39M | 9.1x | 9.2x | 267.1x | 402.4x | |||
| $4.7B | $1.3B | 4.9x | 4.2x | 17.5x | 11.1x | |||
| $895M | $302M | 4.9x | 4.8x | 14.4x | 14.5x | |||
| $732M | $98M | 5.6x | 5.3x | 42.0x | 62.0x | |||
| $602M | $125M | 2.1x | 2.2x | 10.1x | 10.3x | |||
| $378M | $39M | 2.1x | 1.9x | 20.5x | 11.3x | |||
| $606M | $133M | 0.7x | 0.8x | 3.1x | 3.6x | |||
| $176M | $17M | 2.3x | - | 22.9x | - | |||
This data is available for Pro users. Sign up to see all New England Patriots competitors and their valuation data. Start Free Trial | ||||||||
Common questions about New England Patriots
| When was New England Patriots founded? | New England Patriots was founded in 1959. |
| Where is New England Patriots headquartered? | New England Patriots is headquartered in Boston, MA, United States. |
| Is New England Patriots publicly listed? | No, New England Patriots is a private, VC-backed company. |
| What is New England Patriots' valuation? | New England Patriots was last valued at $9B in its undisclosed-stage round in September 2025. |
| How much funding has New England Patriots raised? | New England Patriots has raised $720M across 1 funding round. |
| What was New England Patriots' last funding round? | New England Patriots' last funding round was a $720M undisclosed-stage round in September 2025, led by C. Dean Metropoulos and Sixth Street. |
| Who are New England Patriots' investors? | New England Patriots' investors include C. Dean Metropoulos and Sixth Street. |
| Which companies are comparable to New England Patriots? | Companies comparable to New England Patriots include Suning Sports, Cleveland Browns, Columbus Crew SC, Chicago Bears, MSG Sports and TKO. |
| How many companies has New England Patriots invested in? | New England Patriots has invested in 1 company, including Spero Therapeutics. |
| What was New England Patriots' last investment? | In June 2015, New England Patriots invested in Spero Therapeutics' $30M Series A alongside GSK, SR One, Atlas Venture and 4 other investors. |
See companies similar to New England Patriots
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




